Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free CREO Stock Alerts

Creo Medical Group (CREO) Competitors

Creo Medical Group logo
GBX 14.11 -0.14 (-0.98%)
As of 11:44 AM Eastern
Compare

CREO vs. NIOX, EKF, IUG, NCYT, and IHC

Should you buy Creo Medical Group stock or one of its competitors? MarketBeat compares Creo Medical Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Creo Medical Group include NIOX Group (NIOX), EKF Diagnostics (EKF), Intelligent Ultrasound Group (IUG), Novacyt (NCYT), and Inspiration Healthcare Group (IHC). These companies are all part of the "medical devices" industry.

How does Creo Medical Group compare to NIOX Group?

Creo Medical Group (LON:CREO) and NIOX Group (LON:NIOX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

44.1% of Creo Medical Group shares are held by institutional investors. Comparatively, 7.6% of NIOX Group shares are held by institutional investors. 6.9% of Creo Medical Group shares are held by company insiders. Comparatively, 5.1% of NIOX Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Creo Medical Group had 5 more articles in the media than NIOX Group. MarketBeat recorded 5 mentions for Creo Medical Group and 0 mentions for NIOX Group. Creo Medical Group's average media sentiment score of 1.27 beat NIOX Group's score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the media.

Company Overall Sentiment
Creo Medical Group Positive
NIOX Group Neutral

Creo Medical Group currently has a consensus target price of GBX 40, suggesting a potential upside of 183.49%. NIOX Group has a consensus target price of GBX 86, suggesting a potential upside of 49.83%. Given Creo Medical Group's higher possible upside, analysts plainly believe Creo Medical Group is more favorable than NIOX Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Creo Medical Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Creo Medical Group has a beta of 1.6212822, meaning that its share price is 62% more volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

NIOX Group has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£6M11.42-£25.04M£1.0014.11
NIOX Group£48.70M4.96£995.88M£1.6435.00

Creo Medical Group has a net margin of 88.33% compared to NIOX Group's net margin of 14.37%. NIOX Group's return on equity of 10.14% beat Creo Medical Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group88.33% 9.56% -20.09%
NIOX Group 14.37%10.14%3.95%

Summary

Creo Medical Group and NIOX Group tied by winning 8 of the 16 factors compared between the two stocks.

How does Creo Medical Group compare to EKF Diagnostics?

EKF Diagnostics (LON:EKF) and Creo Medical Group (LON:CREO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

In the previous week, Creo Medical Group had 5 more articles in the media than EKF Diagnostics. MarketBeat recorded 5 mentions for Creo Medical Group and 0 mentions for EKF Diagnostics. Creo Medical Group's average media sentiment score of 1.27 beat EKF Diagnostics' score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the news media.

Company Overall Sentiment
EKF Diagnostics Neutral
Creo Medical Group Positive

EKF Diagnostics currently has a consensus target price of GBX 35, suggesting a potential upside of 36.72%. Creo Medical Group has a consensus target price of GBX 40, suggesting a potential upside of 183.49%. Given Creo Medical Group's higher possible upside, analysts clearly believe Creo Medical Group is more favorable than EKF Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Creo Medical Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

22.0% of EKF Diagnostics shares are owned by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are owned by institutional investors. 40.0% of EKF Diagnostics shares are owned by insiders. Comparatively, 6.9% of Creo Medical Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

EKF Diagnostics has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EKF Diagnostics£51.56M2.14£4.68M£0.4754.47
Creo Medical Group£6M11.42-£25.04M£1.0014.11

EKF Diagnostics has a beta of 0.513, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.6212822, meaning that its stock price is 62% more volatile than the broader market.

Creo Medical Group has a net margin of 88.33% compared to EKF Diagnostics' net margin of 4.12%. Creo Medical Group's return on equity of 9.56% beat EKF Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
EKF Diagnostics4.12% 3.01% 5.27%
Creo Medical Group 88.33%9.56%-20.09%

Summary

Creo Medical Group beats EKF Diagnostics on 9 of the 16 factors compared between the two stocks.

How does Creo Medical Group compare to Intelligent Ultrasound Group?

Creo Medical Group (LON:CREO) and Intelligent Ultrasound Group (LON:IUG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

Creo Medical Group has a net margin of 88.33% compared to Intelligent Ultrasound Group's net margin of -23.11%. Creo Medical Group's return on equity of 9.56% beat Intelligent Ultrasound Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group88.33% 9.56% -20.09%
Intelligent Ultrasound Group -23.11%-23.58%-13.51%

Intelligent Ultrasound Group has higher revenue and earnings than Creo Medical Group. Intelligent Ultrasound Group is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£6M11.42-£25.04M£1.0014.11
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A

44.1% of Creo Medical Group shares are owned by institutional investors. Comparatively, 75.5% of Intelligent Ultrasound Group shares are owned by institutional investors. 6.9% of Creo Medical Group shares are owned by insiders. Comparatively, 12.8% of Intelligent Ultrasound Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Creo Medical Group had 5 more articles in the media than Intelligent Ultrasound Group. MarketBeat recorded 5 mentions for Creo Medical Group and 0 mentions for Intelligent Ultrasound Group. Creo Medical Group's average media sentiment score of 1.27 beat Intelligent Ultrasound Group's score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the media.

Company Overall Sentiment
Creo Medical Group Positive
Intelligent Ultrasound Group Neutral

Creo Medical Group has a beta of 1.6212822, suggesting that its stock price is 62% more volatile than the broader market. Comparatively, Intelligent Ultrasound Group has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Summary

Creo Medical Group beats Intelligent Ultrasound Group on 7 of the 12 factors compared between the two stocks.

How does Creo Medical Group compare to Novacyt?

Creo Medical Group (LON:CREO) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

44.1% of Creo Medical Group shares are held by institutional investors. Comparatively, 10.7% of Novacyt shares are held by institutional investors. 6.9% of Creo Medical Group shares are held by insiders. Comparatively, 0.4% of Novacyt shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Creo Medical Group has a beta of 1.6212822, meaning that its share price is 62% more volatile than the broader market. Comparatively, Novacyt has a beta of 1.105, meaning that its share price is 11% more volatile than the broader market.

Creo Medical Group has a net margin of 88.33% compared to Novacyt's net margin of -91.16%. Creo Medical Group's return on equity of 9.56% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group88.33% 9.56% -20.09%
Novacyt -91.16%-64.86%-27.98%

In the previous week, Creo Medical Group had 5 more articles in the media than Novacyt. MarketBeat recorded 5 mentions for Creo Medical Group and 0 mentions for Novacyt. Creo Medical Group's average media sentiment score of 1.27 beat Novacyt's score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the media.

Company Overall Sentiment
Creo Medical Group Positive
Novacyt Neutral

Creo Medical Group has higher earnings, but lower revenue than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£6M11.42-£25.04M£1.0014.11
Novacyt£20.03M1.29-£36.80M-£32.00N/A

Summary

Creo Medical Group beats Novacyt on 12 of the 13 factors compared between the two stocks.

How does Creo Medical Group compare to Inspiration Healthcare Group?

Creo Medical Group (LON:CREO) and Inspiration Healthcare Group (LON:IHC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

In the previous week, Creo Medical Group had 5 more articles in the media than Inspiration Healthcare Group. MarketBeat recorded 5 mentions for Creo Medical Group and 0 mentions for Inspiration Healthcare Group. Creo Medical Group's average media sentiment score of 1.27 beat Inspiration Healthcare Group's score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the media.

Company Overall Sentiment
Creo Medical Group Positive
Inspiration Healthcare Group Neutral

Creo Medical Group has a beta of 1.6212822, indicating that its stock price is 62% more volatile than the broader market. Comparatively, Inspiration Healthcare Group has a beta of 0.872, indicating that its stock price is 13% less volatile than the broader market.

Inspiration Healthcare Group has higher revenue and earnings than Creo Medical Group. Inspiration Healthcare Group is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£6M11.42-£25.04M£1.0014.11
Inspiration Healthcare Group£47.55M0.37-£12.20M-£1.16N/A

44.1% of Creo Medical Group shares are held by institutional investors. Comparatively, 7.4% of Inspiration Healthcare Group shares are held by institutional investors. 6.9% of Creo Medical Group shares are held by insiders. Comparatively, 6.1% of Inspiration Healthcare Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Creo Medical Group has a net margin of 88.33% compared to Inspiration Healthcare Group's net margin of -2.19%. Creo Medical Group's return on equity of 9.56% beat Inspiration Healthcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group88.33% 9.56% -20.09%
Inspiration Healthcare Group -2.19%-6.49%-3.47%

Summary

Creo Medical Group beats Inspiration Healthcare Group on 10 of the 13 factors compared between the two stocks.

Get Creo Medical Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for CREO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CREO vs. The Competition

Export
MetricCreo Medical GroupMedical Devices IndustryMedical SectorLON Exchange
Market Cap£68.55M£2.09B£6.90B£2.77B
Dividend YieldN/A2.68%2.67%6.15%
P/E Ratio14.1114.6627.42367.98
Price / Sales11.42127.71495.2684,550.77
Price / Cash2.4315.9949.3127.87
Price / Book1.084.7011.027.68
Net Income-£25.04M£144.75M£3.57B£5.89B
7 Day Performance0.36%0.11%0.41%-0.61%
1 Month Performance6.09%1.18%5.76%-0.87%
1 Year Performance12.88%-1.01%31.26%61.83%

Creo Medical Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CREO
Creo Medical Group
N/AGBX 14.11
-1.0%		GBX 40
+183.5%		+16.6%£68.55M£6M14.11279
NIOX
NIOX Group
N/AGBX 59.55
+0.9%		GBX 86
+44.4%		-15.9%£250.63M£48.70M36.3192
EKF
EKF Diagnostics
N/AGBX 26.30
flat		GBX 35
+33.1%		-5.2%£113.22M£51.56M55.96356
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57MN/A65
NCYT
Novacyt
N/AGBX 34.50
flat		N/A-13.3%£24.99M£20.03MN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CREO) was last updated on 7/9/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel